




Sales, NI & Operating CF, annually


Takeda Pharmaceutical Company Limited engages products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hygvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing





- -60,000,000 %





2500 -

Price vs shares outstanding, quarterly


Sales, NI & Operating CF, quarterly

2 250 M -


2.000 M -


0 M -

netincome





Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents,






Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents,







Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents,







Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.







pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the






pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the






pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the









develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions.









PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.





Grape King Bio Ltd produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy foods in Taiwan, China, and internationally. It operates through Multi-Level Marketing, Distributors, and Original Design Manufacturer/Original Equipment Manufacturer (ODM/OEM) segments. The company offers mushroom mycelium products, such as ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor; probiotics, including enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium; and enzymes. It also provides OEM, ODM, formulation design, research and development, and raw material supply services. The company was founded in 1969 and is headquartered in Taoyuan, Taiwan.



-100 M -

Price vs shares outstanding, quarterly


Sales, NI & Operating CF, quarterly

6,000 M -

4,000 M -

2,000 M -

0 M -



production, as well as nutritional health products,

including enzymes, probiotics, and prebiotics; and

parasiticides, and other products used in ruminant

farmers, as well as pork, poultry, and aquaculture

operations. Elanco Animal Health Incorporated was

and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm

a range of vaccines, antibiotics, implants,


animal producers, including beef and dairy

founded in 1954 and is headquartered in

Sales, NI & Operating CF, annually

6 000 M -

netincome



-100 M -

Price vs shares outstanding, quarterly


Sales, NI & Operating CF, quarterly

6,000 M -

4,000 M -

2,000 M -

0 M -



production, as well as nutritional health products,

including enzymes, probiotics, and prebiotics; and

parasiticides, and other products used in ruminant

farmers, as well as pork, poultry, and aquaculture

operations. Elanco Animal Health Incorporated was

and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm

a range of vaccines, antibiotics, implants,


animal producers, including beef and dairy

founded in 1954 and is headquartered in

Sales, NI & Operating CF, annually

6 000 M -

netincome




Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise



4.000 M -

2.000 M -

0 M -



products for the pain management and urology. The company's Sterile Injectables segment

manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist;

and APLISOL, which is a sterile aqueous solution, as

well as generic sterile injectable products,

Sales, NI & Operating CF, annually

netincome



0 M -

0 M -


1,000 M -


750 M -


500 M -

250 M -


0 M -










Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.






segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back-office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers flowers, pre-rolls, flower pods, and dry-herb vaporizer cartridges; concentrates for vaporizing, such as pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, including distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. The company also provides hemp-based CBD products. As of April 21, 2022, it operated 128 dispensaries and 26 cultivation sites in 23 states of the United States. The company was founded in 2010 and is headquartered in Wakefield,






Sales, NI & Operating CF, annually


individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23









markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AVKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental







markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AVKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental




120.0 -


Price vs shares outstanding, quarterly


Sales, NI & Operating CF, quarterly

175 M -




Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.





Green Thumb Industries Inc. engages in manufacture, distribution, and sale of various cannabis products for medical and adult-use in the United States. It offers cannabis flower; and processed and packaged products, including pre-rolls, concentrates, vapes, tinctures, edibles, topicals, and other cannabis-related products under the Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. The company distributes its products primarily to third-party retail stores, as well as sells finished products directly to consumers in its own retail stores. As of April 11, 2022, it owned and operated 77 retail stores in the United States. The company was founded in 2014 and is headquartered in Chicago, Illinois.





-40 M -

-60 M -

-80 M -

-100 M -

-120 M -

-140 M -

-160 M -

Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly


4.000 M -

3,000 M -

2,000 M -

1.000 M -

0 M -



flowers, oils, vapes, edibles, and topicals. It has operations in Canada, the United States, Europe,

internationally. The company was formerly known

as Tilray, Inc. Tilray Brands Inc. was incorporated in

2018 and is headquartered in New York, New York.


Australia, New Zealand, Latin America, and

Sales, NI & Operating CF, annually


600 M -


400 M -


netIncome

















subsidiaries, operates as a medical cannabis company. It cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as through home delivery. The company produces flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, and Roll One brands. As of March 16, 2022, it operated 162 dispensaries, which included 113 dispensaries in Florida, 19 affiliated dispensaries in Pennsylvania, 17 dispensaries in Arizona, five dispensaries in California, three dispensaries in Maryland, two dispensaries in Massachusetts, two dispensaries in West Virginia, and one dispensary in Connecticut. Trulieve Cannabis Corp. also operated cultivation and processing facilities in Arizona, Colorado, Florida, Maryland, Massachusetts, Nevada, Pennsylvania, and West Virginia. The company was formerly known as Schyan Exploration Inc. / Exploration Schyan Inc. and changed its name to





Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to






Sales, NI & Operating CF, annually

netIncome





Sales, NI & Operating CF, annually

netIncome



-20 M -

-40 M -

-60 M -

-80 M -

1.000 M -

800 M -

600 M -

400 M -

200 M -

0 M -



hematological cancers and certain chronic immune

develops Tazemetostat, an inhibitor of EZH2 for the

(phosphoinositide 3'-kinase delta). In addition, it

diseases; and HMPL-689 for isoform PI3Kd

treatment of certain epithelioid sarcoma and

Sales, NI & Operating CF, annually

300 M -

200 M -

netincome



-50 M -

-75 M **–**


70.0 -

Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly

200 M -

0 M -



off episodes in patients with advanced Parkinson's

cervical dystonia and sialorrhea in adults; GOCOVRI

experiencing off episodes; MYOBLOC, a Type B

toxin product indicated for the treatment of

Disease (PD); XADAGO for treating

levodopa/carbidopa in patients with PD

Sales, NI & Operating CF, annually


600 M -

500 M -

revenue

netIncome





-200 M -


-400 M -

600 M -

400 M -

200 M -


0 M -



Sales, NI & Operating CF, annually

1.600 M -

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.




-100 M -

400 M -

200 M -

0 M -

HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.



0 M -

-5 M -

-10 M -

-15 M -

-20 M -

-25 M -

1,200 M -

1.000 M -

800 M -

600 M -

400 M -

200 M -

0 M -


and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. As of January 27, 2022, it owned and operated 48 dispensaries. The company was incorporated in 1990 and is headquartered in



Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasiticides, behavior, internal medicine, and reproduction for cats, dogs, cattle, and pigs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a

2017 FY

2015 FY



600 0 -

Price vs shares outstanding, quarterly


Sales, NI & Operating CF, quarterly

100 M -


200 M -


0 M -


netIncome
operatingCashFlow




HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruguintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and







Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It



-200 M -

-250 M -


-300 M -

400 M -

200 M -

0 M -

enhance the lives of cancer patients by addressing (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.



-200 M -

-250 M -

-300 M -

400 M -

200 M -


0 M -

enhance the lives of cancer patients by addressing (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.



-160 M -

0 M -



implants focused on retinal diseases. It has a

is headquartered in Durham, North Carolina.

agreement with DSM Biomedical. Aerie

collaborative research, development, and licensing

Pharmaceuticals, Inc. was incorporated in 2005 and

Sales, NI & Operating CF, annually

300 M -

200 M -


netIncome

operatingCashFlow



-160 M -

0 M -



implants focused on retinal diseases. It has a

is headquartered in Durham, North Carolina.

agreement with DSM Biomedical. Aerie

collaborative research, development, and licensing

Pharmaceuticals, Inc. was incorporated in 2005 and


Sales, NI & Operating CF, annually

300 M -

200 M -

netIncome

operatingCashFlow



-10 M -

-15 M -

Price vs shares outstanding, quarterly

2019

Sales, NI & Operating CF, quarterly

300 M -

100 M -

0 M -



VetIQ, Capstar, Advecta, SENTRY, Sergeants,

PetLock, Heart Shield Plus, TruProfen, Betsy Farms,

PetAction, Minties, Vera, and Delightibles brands. In

Sales, NI & Operating CF, annually

1 000 M -

netIncome

operatingCashFlow



-50 M -

-75 M -

-100 M -

-125 M -

-150 M -

-175 M -

-200 M -

-225 M -


totalStockholdersEquity

800 M -


600 M -


400 M -

200 M -










Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.




70 -


Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly

200 M -



iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States. It offers biomass products, such as pre-rolls; cannabis infused products, including topical creams and edibles; vape cartridges, concentrates, live resins, wax products, oils, and tinctures; cannabidiol products, such as topical creams, tinctures, and sprays, as well as products for beauty and skincare that include lotions, creams, haircare products, lip balms, and bath bombs. The company engages in the wholesale-distribution and retail of CBD products. It owns and/or operates 31 dispensaries and 10 cultivation and/or processing facilities in 8 states. The company was founded in 2014 and is headquartered in New York, New York.



-140 M -

-160 M -

-180 M -

400 M -


300 M -


200 M -


100 M -















commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly, a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved







Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.







Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.






Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.







ом –

-50 M -

-100 M -

-150 M -

-200 M -

-250 M -

-300 M -

-350 M -

-400 M -

cashAndCashEquivalents

| totalStockholdersEquity

5.000 M -

4.000 M -


3,000 M -


2,000 M -

1,000 M -

0 M -

research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis





4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates in two segments, THC Cannabis and Cannabidiol (CBD) Wellness. It produces, cultivates, sells, and distributes cannabis and CBD. As of December 31, 2021, it operated six dispensaries in Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. In addition, the company sells equipment, supplies, and intellectual property to cannabis producers; imports and sale equipment and supplies; leases real estate properties to cannabis producers; offers consulting services; and operates cannabis dispensaries. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.



50 M -

25 M -

-25 M -

-50 M -

-75 M -

2002 - 2003 - 2004 - 2004 - 2005 - 2005 - 2006 - 2006 - 2006 - 2007 - 2007 - 2011 - 2012 - 2017 - 2018 - 2018 - 2018 - 2018 - 2018 - 2019 - 2019 - 2019 - 2019 - 2011 - 20

350 M -

300 M -


250 M -

200 M -


150 M -

100 M -

50 M -







Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly



Sales, NI & Operating CF, annually

250 M -

Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic




-40 M -

-50 M -

-60 M -

50 M -

25 M -





-1 M -


-2 M -



-80 M -

-100 M -

0 M -





Sales, NI & Operating CF, annually


100 M -

2021


exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.







Red White & Bloom Brands Inc. engages in the cultivation and retail of cannabis products primarily in Michigan, Illinois, Massachusetts, Arizona, California, and Florida. The company is headquartered in Vancouver, Canada.



-30 M **-**

-40 M -

-50 M -


300 M -

200 M -

100 M -

0 M -

products, including cannabis flowers, cannabis oils, Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.



-30 M **-**

-40 M -

-50 M -

300 M -

200 M -

100 M -

0 M -

products, including cannabis flowers, cannabis oils, Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.




-30 M **-**

-35 M -

2005 2006 2007 2008 2010 2011 2012 2014 2015 2015 2015 2017 2018

20 M -

0 M -



Sales, NI & Operating CF, annually

80 M -

- 180 %


commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.



-70 M -


-80 M -

2019



Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.





-10 M -

25 M -

0 M -

Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and



-160 M -

2016


2020

2021

Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly

0 M -





Sales, NI & Operating CF, annually

200 M -

netincome

which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for





neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis. including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio



20 M -

10 M -

0 M -

-10 M -

-20 M -

-30 M -


100 M -


60 M -

40 M -

20 M -

ом -





-7 M -

-10 M -

-12 M -

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.




-20 M -

40 M -

20 M -

Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis,

Minnesota.



-20 M -

-30 M ·

-40 M -


100 M -


75 M -

25 M -


0 M -

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual





MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the MedMen Red and LuxLyte brand names. As of December 25, 2021, it operated 29 stores in California, Florida, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen Enterprises Inc. is headquartered in Culver City, California.



ом –

ом –


0 M -


0 M -

0 M -

0 M -

0 M -





2009 2010 2011 2013 2014 2015 2016 2017 2018 2019 2020

150 M -

100 M -

50 M -

-50 M -

-100 M -

70.000 M - totalStockholdersEquity

60,000 M -


50,000 M -


40,000 M -

30,000 M -

20,000 M -


10,000 M -





RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical

Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies



2021

-20 M -

-22 M -



-2 M -

-5 M -

-7 M -

-10 M -

-12 M -

-15 M -


-17 M -


250 M -

150 M -

100 M -

50 M -





10 M -

5 M -

0 M -

-5 M 🗕

-10 M -

-15 M -

-20 M -

3,500 M -

3,000 M -

2.500 M -


2,000 M -


1,500 M -

1.000 M -


500 M -







Sundial Growers Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Cannabis Operations and Retail Operations segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use markets; and private sale of recreational cannabis through corporate owned and franchised retail cannabis stores. The company also produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. Sundial Growers Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.



1 M -

0 M -

-1 M -

-2 M -

-3 M -

-4 M -

-5 M -

30 M -

25 M -

20 M -

15 M -

10 M -

5 M -

0 M -



Sales, NI & Operating CF, annually

30 M -

25 M -

20 M -

15 M -

10 M -


revenue

netincome

Henderson, Nevada.

2021

operatingCashFlow



0 M

-2 M -

-4 M -

-6 M -

-8 M -

-10 M -

-12 M -

-14 M -

-16 M -

-18 M -

totalStockholdersEquity

500 M -


400 M -


300 M -


200 M -

100 M -

ом -








4 M -

40 M -


20 M -

0 M -



ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. ECO Animal Health Group plc was founded in 1972 and is headquartered in New Malden, the United Kingdom.





2021

2 M -

0 M -

-2 M 🗕

-4 M -

-6 M -

-8 M -

-10 M -

-12 M -

longTermDebt shortTermDebt

250 M -

200 M -


150 M -


100 M -


50 M -

ом -

cashAndCashEquivalents totalStockholdersEquity







IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, and pressed hash offerings under the WAGNERS and Highland Grow brands. The company serves medical patients and adult-use recreational consumers. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.



2020

0 M -

0 M -

0 M -

0 M -

0 M -

0 M -

0 M -

0 M -


0 M -


0 M -


0 M -

ом -

0 M -







о м

-10 M

-20 M -

-30 M -

-40 M -

-50 M -

-60 M -

175 M - totalStockholdersEquity

150 M -


125 M -


100 M -

75 M -

25 M -







Millennium Sustainable Ventures Corp. is a close-ended investment company. The firm primarily intends to effect a merger, capital stock exchange, asset acquisition, or other similar transaction with one or more businesses that have operations primarily in India. It seeks to invest in companies operating in the financial services sector, healthcare, infrastructure and consumer, retail, and hospitality sectors. The firm primarily invests in private equity of SMC Group. It was formerly known as Millennium India Acquisition Company Inc. Millennium Sustainable Ventures Corp. was formed on March 15, 2006 and is domiciled in the United States.



-60 M -

-70 M -

20.0 -


Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly

40 M -

20 M -

0 M -



soluble film formulation of diazepam for the

treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its

proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation

delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a

Sales, NI & Operating CF, annually

80 M -

60 M -

netincome

operatingCashFlow



-120 M -

2016

2020

2021

25.0 -

Price vs shares outstanding, quarterly


Sales, NI & Operating CF, quarterly


10 M -

ом -

2018 FY 2021 FY Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala

Sales, NI & Operating CF, annually





2 M -

-2 M -

-5 M -

-10 M -

-12 M -

-15 M -

shortTermDebt

35 M -

30 M -

25 M -

15 M -


10 M -


5 M -


0 M -

cashAndCashEquivalents

totalStockholdersEquity










radiopharmaceutical and radiochemical contract manufacturing services in the United States and internationally. It operates through five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. It offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items. The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources. The Radiochemical Products segment produces and distributes various

isotopically pure radiochemicals and sodium iodide







Generation Hemp Inc. engages in leasing industrial warehouse located in Denver, Colorado. The company was formerly known as Home Treasure Finders, Inc. and changed its name to Generation Hemp Inc. in August 2019. Generation Hemp Inc. was incorporated in 2008 and is based in Dallas, Texas.













Endexx Corporation engages in the manufacturing and sale of cannabidiol (CBD)-based products for the health and wellness market. It provides CBD creams, oils, capsules, extracts, topicals, drinks, chocolates, and pet products, as well as hemp-derived health and beauty care products for supporting the therapeutic relief of pain and inflammation for humans and pets through its e-commerce site cbdunlimited.com, as well as other online and in-store retailers. The company was formerly known as CBD Unlimited, Inc. and changed its name to Endexx Corporation in May 2020. Endexx Corporation is headquartered in Cave Creek, Arizona.









Lowell Farms Inc. engages in the cultivation, extraction, manufacturing, sale, marketing, and distribution of cannabis products to retail dispensaries in California. The company provides flowers, vape pens, oils, extracts, chocolate edibles, mints, gummies, topicals, tinctures, and pre-rolls under the Lowell Herb Co., Lowell Smokes, Cypress Reserve, Flavor Extracts, Kaizen, House Weed, Moon, Altai, Humble Flower, Original Pot Company, and CannaStripe brands. It also offers manufacturing, extraction, and distribution services to third-party cannabis and cannabis branding companies. The company was formerly known as Indus Holdings, Inc. and changed its name to Lowell Farms Inc. in March 2021. Lowell Farms Inc. was founded in 2014 and is based in Salinas, California.









CordovaCann Corp., a cannabis-focused consumer products company, primarily provides services and investment capital to the processing, production, and retail vertical markets of the cannabis industry. As of February 14, 2022, it operated 14 stores under the Star Buds Cannabis Co. brand in Canada and the United States. The company was formerly known as LiveReel Media Corporation and changed its name to CordovaCann Corp. in January 2018. CordovaCann Corp. is based in Toronto, Canada.






Healthy Extracts Inc., through its subsidiaries, researches, develops, and markets natural plant-based formulations in the United States and internationally. It offers heart health nutritional products; and neuro-products under the KETONOMICS name that enhance brain health, including memory, cognition, focus, and neuro-energy. The company also provides bergamot products in capsule form under the BergaMet Pro+, BergaMet Mega+O, BergaMet HERHEART, BergaMet Cholesterol Command, and BergaMet SPORTSHEART products labels. It distributes bergamot products through its website and distribution sites. The company was formerly known as Grey Cloak Tech Inc. and changed its name to Healthy Extracts Inc. in October 2020. Healthy Extracts Inc. was incorporated in 2014 and is based in Las Vegas, Nevada.









Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.





Sales, NI & Operating CF, annually

High Sierra Technologies, Inc. focuses on the development of patents and other products used in the processing of recreational cannabis and industrial hemp. Its patent portfolio includes low odor cannabis and hemp for smoking or as the starting materials for producing low odor cannabis and hemp products or flavored cannabis and hemp products. The company is based in Reno, Nevada.




2021


ом –

Gridiron BioNutrients, Inc. develops, markets, and sells cannabidiol products. The company offers capsules, oil, gummies, concentrates, water, beverages, hemp tinctures, and salves. It sells its products under the Gridiron BioNutrients and Gridiron MVP names through an online platform. The company was founded in 2014 and is based in


- -500 %


2021 FY






dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.






Exactus, Inc. produces and supplies hemp-derived ingredients and feminized hemp genetics. It provides cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products to the cosmetic, wellness, food, beverage, pharmaceutical, and pet industries. The company's specialty ingredients include CBD, CBG, CBN, and CBC isolates; CBD and CBG distillates; CBD water-soluble; CBD and CBG biomass; CBD AND CBG flowers; and CBD crude oil. It also provides a range of custom manufactured specialty cannabinoid products, such as skincare products, pain creams, tinctures, bath bombs, soft gels, balms, pet products, supplements, and other products. The company is based in Delray Beach, Florida. Exactus, Inc. is a subsidiary of Ceed2Med, LLC.







Sales, NI & Operating CF, annually


MJ Holdings, Inc. operates in the medical marijuana business in Nevada. It offers cultivation and production management, consulting, and asset and infrastructure development services for the cannabis industry. The company is headquartered in Las Vegas, Nevada.


















Stem Holdings, Inc. operates as a vertically-integrated cannabis products and technology company. It engages in the production, distribution, and sale of cannabis and cannabis-infused products. The company's brands include TJ's Gardens, TravisxJames, and Yerba Buena flower and extracts; Cannavore edible confections; Doseology, a CBD mass-market brand; and delivery-as-a-service brands of Budee and Ganjarunner e-commerce platforms. As of September 30, 2021, it had ownership interests in 29 state issued cannabis licenses, including 9 licenses for cannabis cultivation; 3 licenses for cannabis processing; 2 licenses for cannabis wholesale distribution; 3 licenses for hemp production; 7 cannabis dispensary licenses; and 5 licenses for adult-use medical retailers. The company was incorporated in 2016 and is headquartered in Boca Raton, Florida.







Can B Corp. develops, manufactures, and sells cannabidiol (CBD) based products in the United States. The company provides CBD products derived from hemp, including oils, creams, moisturizers, isolate, gel caps, spa products, concentrates, and life style products through its Website and vending machines, and other medical professionals. It offers its products under the Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil brands. The company was formerly known as Canbiola Inc. and changed its name to Can B Corp. in February 2020. Can B Corp. was incorporated in 2005 and is based in Hicksville, New York.







Indoor Harvest Corp. focuses on providing production platforms, mechanical systems, and complete custom designed build outs for controlled environment agriculture and building integrated agriculture for the cannabis industry. The company also provides consulting and other services. Indoor Harvest Corp. was founded in 2011 and is based in Austin, Texas.









0 M -

-1 M 🗕

-1 M -

-2 M -

-2 M -

-3 M -

-3 M -

4 M -

3 M -





2020

2021

-2 M -

-4 M -

-6 M -

-8 M **-**

-10 M -

-12 M -

-14 M -

-16 M -

-18 M -

140 M - totalStockholdersEquity

120 M -


100 M -

80 M -

60 M -

20 M -

ом –






-4 M -

4.0 -


Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly

500 M -



One World Products, Inc. produces and supplies various cannabis and hemp products worldwide. It provides cannabis, hemp, and hemp products, including derivatives in crude oil, distillate, and isolate forms. The company was formerly known as One World Pharma, Inc. and changed its name to One World Products, Inc. in November 2021. One World Products, Inc. is headquartered in Las Vegas, Nevada.




2020


0 M -


0 M -





Grapefruit USA, Inc. focuses on manufacturing and distribution of cannabis distillates, edibles, and cannabis products. It also offers cannabis advisory services for branding, compliance, packaging, extraction, edible manufacturing, and distribution logistics efforts. The company was formerly known as Grapefruit Boulevard Investments, Inc. and changed its name to Grapefruit USA, Inc. in January 2020. Grapefruit USA, Inc. was founded in 2017 and is based in Wilmington, Delaware.







-10 M -

-20 M -


-30 M -


-40 M -

60 M -

20 M -

ом –





2020 FY




-3 M -

Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly

0 M -




Sales, NI & Operating CF, annually

4 M -

revenue

netIncome

Kona Gold Beverage, Inc. develops and sells hemp and cannabidiol (CBD) products in the functional beverage and fitness markets in the United States. The company operates through two segments, Beverages and Distribution. It offers hemp energy drinks and CBD energy water; and alkaline waters, beverages for kids, energy drinks, fruit flavored sodas, low carb lemonade, healthy aloe juice drinks, and CBD-infused jellybeans. The company also sells merchandise and apparel, such as shirts, tanks, hats, and towels. It sells its products primarily to beverage distributors and resellers, retail grocery, smoke shops and specialty stores, wholesalers, merchandisers, vape shops, and convenience stores; and beverage services under the Kona Gold Hemp Energy Drinks, OOH LA LEMIN, and Highdrate names. The company was formerly known as Kona Gold Solutions, Inc. and changed its name to Kona Gold Beverage, Inc. in October 2020. Kona Gold Beverage, Inc. was incorporated in 1997 and is based in Melbourne, Florida.



-1 M -

-1 M -


-2 M -


2 M -

1 M -

0 M -

provides standing display cases with cannabis intended glassware under the Really Happy Glass brand; and t-shirt designs under the Kaya Gear brand name. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. was incorporated in 1993 and is headquartered in Fort Lauderdale, Florida.






Sales, NI & Operating CF, annually

- 48 %

35 M -



Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.



2019

2020

0 M -

-2 M -

-4 M -

-6 M -


-8 M -


-10 M -

-12 M -


60 M -


40 M -







0 M -







Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.









0 M -

-1 M 🕳

-1 M -

-2 M -

-2 M -

-3 M -

-3 M -


-4 M -

3 M -


2 M -


1 M -

0 M -




- 36 %





Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.





ом -

-1 M -

-2 M -

-3 M -

-4 M -

-5 M -

-6 M -


14 M -


12 M -

10 M -


4 M -








Cannabis Suisse Corp. engages in the cultivation, production, and distribution of over-the-counter products, recreational tobacco products, and medical CBD oils. The company sells its products through Swiss4Life, a retail brand for online selling, as well as a network of retailers. It provides health-related supplements, and face masks and disinfectants, as well as retails cigarettes. The company was formerly known as Geant Corp. and changed its name to Cannabis Suisse Corp. in February 2019. Cannabis Suisse Corp. was incorporated in 2016 and is based in Bell Gardens, California.





2019

0 M -

ом -


0 M -

0 M -


0 M -


0 M -

0 M -













Sales, NI & Operating CF, annually

Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems primarily in the United States. The company offers advanced skin and wound care products, including the hydrogel wound dressing products, post op surgical kits, saline wound washes, care lotions, and barrier lotions to promote healing in wound and problematic skin conditions, as well as hand sanitizer under the AMERIGEL brand name. It also provides Bioactive Collagen products in the form of power and matrix under the HELIX3 brand name. In addition, the company offers wound care products, such as calcium alginate, foam, gauze, and hyrdocolloid dressing products; and wound care kits, which include calcium alginate, collagen matrix, collagen powder, foam, and hydrogel wound care kits under the AMERX brand name, as well as compression garment line products under the EXTREMIT-EASE name. It sells its products through distributors to institutional customers, such as hospitals, wound care clinics, nursing









2007 2008 2009 2010 2011 2012 2014 2016 2016

0 M -

-1 M -

-1 M -

-2 M -

-2 M -

14 M -

12 M -


10 M -


6 M -

4 M -


2 M -








Parallel Industries Inc. does not have significant operations. Previously, the company was involved in development and markets various topically delivered drugs to treat cancer and other therapeutic products to treat various conditions. It focuses on development, licenses, production, and markets prescription and over-the-counter products. The company was formerly known as Easton Pharmaceuticals Inc. and changed its name to Parallel Industries Inc. in December 2020. Parallel Industries Inc. was founded in 1997 and is headquartered in Toronto, Canada.









Golden Developing Solutions, Inc., together with its subsidiaries, engages in developing an online retail business for cannabidiol (CBD) products. It develops and operates an Internet website that offers CBD, hemp oil, and health/wellness related products, including vitamins, supplements, CBD based tinctures, vapes, soft-gels, and other products. The company was formerly known as Clean Hydrogen Producers, Ltd and changed its name to Golden Developing Solutions, Inc. in April 2017. Golden Developing Solutions, Inc. was incorporated in 1998 and is based in Fort Lauderdale, Florida.







CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.







Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.







Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CBD-infused sunscreen under the CaniSun brand; CBD-infused skin care lotion under the CaniSkin brand; and products for the dermatological treatments of pain and inflammation under the CaniDermRX brand. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.



1 M -

-1 M -

-2 M -


1996 - 1 1998 - 1 1998 - 1 1998 - 1 1999 - 1 199

Price vs shares outstanding, quarterly


Sales, NI & Operating CF, quarterly


8 M -

6 M -




Resonate Blends, Inc., a cannabis holding company, provides cannabis-based products. It also operates an online mobile marketing platform that provides various offers, discounts, alerts, and events schedules, such as happy hours, trivia night, and other campaigns. The company was formerly known as Textmunication Holdings, Inc. and changed its name to Resonate Blends, Inc. in December 2019. Resonate Blends, Inc. is based in Calabasas, California.





-5 M -

ом -



ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and

treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for

2015

pain of epigastric cold; Zhitongtougu ointment for

cataract. Its prescription pharmaceutical products

include Danshen granules; Taohuasan pediatric


Sales, NI & Operating CF, annually

100 M -

80 M -

netIncome

operatingCashFlow




-15 M -


-20 M -

2015


20 M -





Shineco, Inc. engages in processing and distributing specialized fabrics, textiles, and other byproducts derived from an indigenous Chinese plant Apocynum Venetum in the People's Republic of China. The company's specialized fabrics, textiles, and other byproducts are specialized textile and health supplement products to incorporate traditional Eastern medicines with various scientific methods. It also grows and cultivates yew trees, fast-growing bamboo willows, and scenic greening trees; and provides logistic services for agricultural products. The company is headquartered in Beijing, the People's Republic of China.





THC Therapeutics, Inc. operates in the wellness industry. It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. The company was formerly known as Millennium Blockchain, Inc. and changed its name to THC Therapeutics, Inc. in September 2018. THC Therapeutics, Inc. was incorporated in 2007 and is based in Las Vegas,


















Veritas Farms, Inc. focuses on producing, marketing, and distributing hemp oils and extracts containing phytocannabinoids. The company's products include vegan capsules, gummies, tinctures, lotions, salves, vape oils, cream, and oral syringes. It markets and sells its products under the Veritas Farms brand name, as well as through white label and private label custom formulations for distributors and retailers. The company was formerly known as SanSal Wellness Holdings, Inc. and changed its name to Veritas Farms, Inc. in February 2019. Veritas Farms, Inc. is based in Fort Lauderdale, Florida.





Black Bird Biotech Inc. provides various biotech products. It manufactures and distributes MiteXstream, a plant-based biopesticide for the eradication of spider mites. The company also manufactures and sells CBD Oils, gummies and pet treats, CBD-infused personal care products, and hand sanitizer gel and spray products under the Grizzly Creek Naturals brand name. In addition, it grows industrial hemp under the Montana Hemp pilot program. The company was formerly known as Digital Development Partners, Inc. and changed its name to Black Bird Biotech, Inc. in June 2021. Black Bird Biotech, Inc. is based in Flower Mound, Texas.







Sales, NI & Operating CF, annually


Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.







Pure Harvest Corporate Group, Inc. focuses on the acquisition and operation of licensed medical and recreational marijuana dispensaries, cultivation facilities, and production facilities. It also focuses on providing cannabis and hemp-derived health and wellness products; and applying education, research and development, and technology to various sectors. The company was formerly known as Pure Harvest Cannabis Group, Inc. and changed its name to Pure Harvest Corporate Group, Inc. in June 2020. Pure Harvest Corporate Group, Inc. was founded in 2004 and is based in Greenwood Village, Colorado.






alternative medicine worldwide. The company focuses on delivering nutritional and dietary supplements for the treatment of chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea, and aging. Its products include hemp oils, vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods, and other products. The company markets its products in a range of formulations and delivery forms, including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. It also offers Cannabidiol oil to retailers in the vaping industry; and cannabinoid products. In addition, the company retails health, wellness, sports nutrition, and dietary supplement products. Earth Science Tech, Inc. offers its products through its retail store, clinics, pharmacies, as well as through online. The company was formerly known as Ultimate Novelty





The Greater Cannabis Company, Inc., a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids. The company's initial product is an oral transmucosal patch platform, which provides loaded actives to be absorbed by the buccal mucosa into the body. It intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer products, and pharmaceutical companies. The company has a license and research agreement with Shaare Zedek Scientific Ltd. to assess the synergistic impact of various combinations of the neuroprotective therapeutic in a preclinical model. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.



0 M -

0 M -


ом –

0 M -


0 M -

0 M -

0 M -



Eco Innovation Group, Inc. focuses on the development of power booster for home and office applications that will reduce electric bills. It also provides other energy saving related technologies. Eco Innovation Group, Inc. is based in Van Nuys, California.



-20 M -

-25 M -

-30 M -

-35 M -

-40 M -

Price vs shares outstanding, quarterly

2021

Sales, NI & Operating CF, quarterly


100 M -

75 M -


50 M -

25 M -

ом -



Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.



2015

0 M -

0 M -

ом -

0 M -

-1 M -

-1 M -


1 M -

1 M -

1 M -

0 M -

0 M -



-10 M

-20 M -

-30 M -

-40 M -

-50 M -

-60 M -


125 M -

100 M -

75 M -


25 M -





-6 M -





1 M -

0 M -

0 M -

0 M -

-1 M -

-1 M -

2020

20 M -

15 M -

10 M -

0 M -



Sales, NI & Operating CF, annually

10 M -

5 M -

2 M -

0 M -

-2 M -

-5 M -

-7 M -

netIncome

operatingCashFlow



-10 M -

-12 M -

-15 M -

-17 M -

5.0 -

Price vs shares outstanding, quarterly


Sales, NI & Operating CF, quarterly

15 M -


20 M -

10 M -

0 M -



Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.




-7 M -

5.0 -


Price vs shares outstanding, quarterly


2020

Sales, NI & Operating CF, quarterly





PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.





Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production and sale of medical cannabis for medical purpose in Canada. It offers dried cannabis strains, pre-rolls, ingestible extracts, and cannabis oil products to its medical patients. The company distributes its medical products through licensed wholesale pharmacies and to licensed wholesale clients. It also exports medical cannabis products to licensed wholesale purchasers in Europe. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.






Sales, NI & Operating CF, annually

revenue netincome

operatingCashFlow



0 M -

-5 M -

-10 M -

-15 M -

-20 M -

-25 M -

-30 M -

-35 M **–**

140 M - totalStockholdersEquity

120 M -


100 M -


80 M -

60 M -

20 M -


ом -





-10 M -


ом -




Sales, NI & Operating CF, annually


70 M -

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. It offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, and hemp frozen age nourishing creams. The company also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, it offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, the company manufactures and sells various types





Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.



-10 M -

-20 M -

-30 M -

-40 M -

-50 M -


120 M -

100 M -

80 M -

60 M -

20 M -







35.0 -

Price vs shares outstanding, quarterly


Sales, NI & Operating CF, quarterly



Ayr Wellness Inc., a vertically-integrated cannabis multi-state operator, cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. The company's cannabis and cannabis products include concentrates, edibles, and vaporizer products. It also provides administrative, consulting, and operations support services to licensed cannabis companies. As of March 25, 2022, Ayr Wellness Inc. operated 45 dispensaries. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.



0 M -




Sales, NI & Operating CF, annually


1 000 M -

800 M -

netIncome

in the research, development, manufacture, and sale of skin-health related medicines worldwide. diseases comprising actinic keratosis, atopic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein





Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.



3,000 M -

2,500 M -

2,000 M -

1,500 M -

1,000 M -

500 M -

totalStockholdersEquity


50,000 M -

40,000 M -


30,000 M -


20,000 M -


10,000 M -
























distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.







2008 2009 2010 2011 2012 2013 2015 2016 2017 2018 2019 2020

20 M -

-20 M -


-40 M -


500 M -

400 M -

300 M -

100 M -





-5 M -

-10 M -

-15 M -


-20 M -


35 M -


30 M -

25 M -

10 M -











Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD, KAMRAB/KEDRAB a plasma-derived hyper- immunoglobulin for prophylactic treatment against rabies infection. It also provides KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults















Nunzia Pharmaceutical Corporation operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute NUNZIA, a drug that treats autism, fragile X, ADHD, and PTSD. It offers its products through wholesalers, as well as through its website www.nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Corporation in February 2018. Nunzia Pharmaceutical Corporation was incorporated in 1986 and is based in Long Beach, California.




-80 M -

-100 M -


-120 M -


200 M -


0 M -




Harvest Health and Recreation, Inc., together with its subsidiaries, cultivates, processes, sells, and retails inhalable, ingestible, and topical cannabis products in the United States. The company offers cannabis oil products; inhalables, including flower, dabbable concentrates, pre-filled vaporizer pens, and cartridges; and capsules, tinctures, and cannabis product edibles, including chocolates, gummies, mints, fruit chews, and dissolvable mouth strips under the Avenue, CBX SCIENCES, EVOLAB, ALCHEMY, CHROMA, CO2LORS, GOODSUN, MODERN FLOWER, and ROLL ONE brand names. It also operates retail dispensaries that sell proprietary and third-party cannabis products to patients and customers; and provides support services and financing to a Utah licensed medical cannabis cultivator. Harvest Health and Recreation, Inc. was founded in 2011 and is headquartered in Tempe, Arizona.











Price vs shares outstanding, quarterly

(100 kg) (10

Sales, NI & Operating CF, quarterly



Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non?narcotic, non?addictive, and over?the?counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and anti?inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological



-1 M -

-2 M -

-3 M -

-4 M -

-5 M -

-6 M -

-7 M -

-8 M -


-9 M -


35 M - totalStockholdersEquity

30 M -

25 M -

20 M -






200 M -

-200 M -

5,000 M -

0 M -




Sales, NI & Operating CF, annually


4 000 M -

2021


netIncome


diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also






company, engages in the research, development, and production of cannabinoid health solutions in the United States. It offers hemp-derived natural health products, including Liberty, a hemp-derived cannabidiol (CBD) tincture; Tactical Hydration, a CBD infused electrolyte replacement drink; FIZZ Tablets for adding in a water bottle; Battle Balm, a CBD roll on activity rub for aches and pains; and Quick Hit, a CBD gummy under the Tactical Relief brand. The company also provides Hydrosport CBD Drink, a CBD infused electrolyte replacement drink with sodium citrate electrolyte replacement; Hydrosport Tincture, a CBD tincture fortified with specific terpene profile; FIZZ Tablets for adding to a water bottle; Sport Rub, a CBD post-activity rub for aches and pains; and Quick Hit, a CBD gummy with vitamin B12 under the Equilibrium Bio brand. In addition, it offers Skin Structure, a facial formula topically applied to enhance skin's radiance and youthfulness; Eye Recover that helps the eye skin ward off free radicals, as well as helping to protect against sun damage; Glossy Lip Recover, which moisturizes and nourishes lips; Skin Designer that





New You, Inc., through its subsidiary, New You LLC, develops and markets cannabidiol (CBD) hemp oil-based products. The company offers DROPS beverage or liquid CBD products; CB2 & CBD 2 Plus, a multi spectrum hemp-extracted CBD and beta-caryophyllene; Drops for pets; Caffe Canna, an organic cannabinoid-infused non-GMO dark roast coffee; and ABSORB, a root and rice flour veggie capsule. It also provides RELEASE; Drops FX, a blend of CBD and Vitamins B3, B6, B9, and B12 for use in drink or liquid; and Drops FX Sleep, a blend of CBD, gamma-amino butyric acid, melatonin, and valerian root; NanoX, a water soluble full spectrum DBD made with Purified Water; and The Cream, a topical skin cream. The company markets and sells its products through multi-level marketing and direct sales force to independent business owners. New You, Inc. is based in Carlsbad, California.




-10 M -

-12 M -

Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly

10 M -



Sales, NI & Operating CF, annually

30 M -


CLS Holdings USA, Inc., a diversified cannabis company, focuses on the extraction and conversion of cannabinoids in the United States. It extracts cannabinoids from the cannabis plants and converts into concentrates, such as oils, waxes, edibles, and shatters. The company sells organic medical cannabis to licensed retailers; recreational marijuana cannabis products to licensed distributors and retailers; extraction products, such as oils and waxes derived from in-house cannabis production; processing and extraction services for licensed medical cannabis cultivators; and cannabis strains in the form of vegetative cuttings to licensed medical cannabis cultivators. It also offers consulting services to cannabis-related businesses comprising growers, dispensaries, and laboratories; and toll processing services. The company provides its products under Oasis Cannabis and City Trees brand names. Its concentrates are used for pharmaceutical and other purposes. The company was founded in 2014 and is based in Miami. Florida.



Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly

0 M -



CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the

Sales, NI & Operating CF, annually

25.000 M -

20,000 M -

netIncome





HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. HEXO Corp. has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau,

- -100 %

2020 FY

2021 FY





EVIO, Inc., together with its subsidiaries, provides analytical testing and advisory services to cannabis industry in the United States. The company's consulting services include advisory, product formulation, and licensing and compliance services. It also offers various testing services comprise cannabinoid potency testing, terpene analysis, pesticide testing, residual solvent screening, visual inspections, biological contaminant testing, and other services. EVIO, Inc. is headquartered in Henderson, Nevada.



0 M

-10 M -


-20 M -

50 M -

0 M -

Medicine Man Technologies, Inc., doing business as Schwazze, operates as a cannabis company. It operates through three segments: Retail, Wholesale, and Other. The company offers cannabis products that include loose flower, concentrates, edibles, pre-rolls, topicals, and other associated cannabis products; and vape cartridges and syringes. As of March 14, 2022, it owned and operated 23 retail cannabis dispensaries under the Star Buds, Smoking Gun Apothecary, Emerald Fields, and Drift banner names in Denver and dispensaries under the R. Greenleaf banner in New Mexico. The company also provides licensing and consulting, facility design, and facility management services; and Three A Light publication. In addition, it manufactures, wholesales, and retails various plant nutrients for cannabis; and supplies hydroponics and indoor gardening supplies. The company was incorporated in 2014 and is headquartered in Denver, Colorado.

2021 FY



2011 2012 2013 2014 2015 2016 2017 2018

125 M -

100 M -

75 M -

50 M -

25 M -

0 M -

-25 M -

-50 M -

1,500 M -

1,250 M -

1,000 M -

750 M -


500 M -

250 M -






2016 FY 2017 FY Pazoo, Inc. operates as a health and wellness company. It offers laboratory testing services for marijuana. Pazoo, Inc.was formerly known as IUCSS, Inc. and changed its name to Pazoo, Inc. in May 2011. The company was founded in 2010 and is headquartered in East Hanover, New Jersey.



0 M -



1-(2-Hydroxyphenyl)-3-phenylpropan-1-one,

(S)-3-(methylmino)-1-(2-thi-enyl)propan-1-ol,

intermediate products also consists of

acid HCl, (1R, 2S)-1

2021

N-Methyl-4-piperidinol, Ritalinic acid, d-Ritalinic

Phenyl-2-(pyrrolldin-1-yl)propan-1-ol HCl, and (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol. Its

Sales, NI & Operating CF, annually

3.000 M -

2,500 M -

netincome




200 M -

Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly

500 M -

0 M -



for chronic and acute diarrhea, and pain associated

constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in

adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. The company provides

with functional bowel diseases; Forlax for

Sales, NI & Operating CF, annually

- 82 %

3.500 M -

3.000 M -

netIncome



-500 M -

-1,000 M -

-1,500 M -


Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly

5,000 M -

2,500 M -

0 M -



offers pharmaceutical regulatory affairs project

Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan. Lotus

Pharmaceutical Co., Ltd. is a subsidiary of Alvogen

management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus


Emerging Markets Holdings Limited.

Sales, NI & Operating CF, annually

14 000 M -

12.000 M -

netIncome




1600 -

Price vs shares outstanding, quarterly


Sales, NI & Operating CF, quarterly

400 M -

0 M -




Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.



Price vs shares outstanding, quarterly

Sales, NI & Operating CF, quarterly



Sales, NI & Operating CF, annually


175 M -

netIncome


operatingCashFlow


Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.







Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of






MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.





2 M -

20 M -



shortTermDebt

700 M -

600 M -

500 M -

400 M -

300 M -


200 M -

100 M -

0 M -

cashAndCashEquivalents totalStockholdersEquity






200 M -

100 M -

1,000 M -

500 M -

0 M -



Sales, NI & Operating CF, annually

3 000 M -

netIncome

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.